SEARCH

SEARCH BY CITATION

References

  • 1
    Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. New Engl J Med 1989; 321: 41924
  • 2
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 14918DOI: 10.1016/s0140-6736(00)02163-2
  • 3
    Bracci U & Di Silverio F. Role of cyproterone acetate in urology. In MartiniL, MottaM eds, Androgens and Antiandrogens. New York: Raven Press, 1977: 3339
  • 4
    Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol 1979; 5: 3036
  • 5
    Di Silverio F, Serio M, D'Eramo G, Sciarra F. Zoladex versus Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer. A multicentre Italian study. Eur Urol 1990; 18 (Suppl. 3): 5461
  • 6
    Labrie F, Dupont A, Belanger A. A complete androgen blockade for the treatment of prostate cancer. In DeVitaVT ed. Advances in Oncology. Philadelphia: JB Lippincott, 1985: 193217
  • 7
    Crawford ED & Nabors WL. Total androgen ablation: American experience. Urol Clin North Am 1991; 18: 5563
  • 8
    Van Tinteren H & Dalesio O. Systematic overview (meta-analysis) of all randomised trials of treatment of prostate cancer. Cancer 1993; 72 (Suppl. 12): 384750
  • 9
    Denis L & Murphy GP. Overview of phase III trials on combined androgen ablation treatment in patients with metastatic prostate cancer. Cancer 1993; 72 (Suppl. 12): 388895
  • 10
    Suciu S, Sylvester R, Iversen P, Christensen I, Denis L. Comparability of prostate trials. Cancer 1993; 72 (Suppl. 12): 38416
  • 11
    Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostate cancer. A meta-analysis of seven randomised double-blind trials (1056 patients). Br J Urol 1994; 73: 396402
  • 12
    McLeod DG, Crawford ED, Blumenstein BA, Eisenberger MA, Dorr FA. Controversies in the treatment of prostate cancer. Cancer 1992; 70: 3248
  • 13
    Tyrrell CJ, Altwein JE, Klippel F et al. A multicentre randomized trial comparing the luteinising hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol 1991; 146: 13216
  • 14
    Tyrrell CJ, Altwein JE, Klippel F et al. Multicentre randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer: Survival update. Cancer 1993; 72 (Suppl. 12): 38789
  • 15
    Lunglmayr G. Zoladex' versus ‘Zoladex’ plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. In Therapeutic Progress in Urological Cancers: Progress in Clinical and Biological Research. New York: Alan R Liss Inc, 1989: 14551
  • 16
    Ferrari P, Castagnetti G, Ferarri G, Pollastri CA, Tavoni F, Dotti A. Combination treatment in M1 prostate cancer. Cancer 1993; 72 (Suppl. 12): 38805
  • 17
    Klijn JGM, De Voogt HF, Studer UE, Schroder FH, Sylvester R, DePauw M. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. Cancer 1993; 72 (Suppl. 12): 385862
  • 18
    De Voogt HJ, Klijn JGM, Studer U et al. Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843. J Steroid Biochem Mol Biol 1990; 37: 9659
  • 19
    Béland G, Elhilali M, Fradet Y et al. Total androgen blockade for metastatic cancer of the prostate. Am J Clin Oncol 1988; 11 (Suppl. 2): S18790
  • 20
    Béland G, Elhilali M, Fradet Y et al. Total androgen ablation: Canadian experience. Urol Clin N Am 1991; 18: 7582
  • 21
    Jorgensen T, Tveter KJ, Jorgensen LH. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study no. 2. Eur Urol 1993; 24: 46670
  • 22
    Janknegt RA for the Anandron International Study Group. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer 1993; 72: 38747
  • 23
    Keuppens F, Whelan P, Carneiro de Moura JL et al. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). Cancer 1993; 72 (Suppl. 12): 38639
  • 24
    Newling WW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer (EORTC 30853). Cancer 1993; 72 (Suppl. 12): 37938
  • 25
    Denis L, Smith P, Carneiro de Moura JL et al. Total androgen ablation: European experience. Urol Clin North Am 1991; 8: 6573
  • 26
    Keuppens F, Denis L, Smith P et al. Zoladex and flutamide versus bilateral orchidectomy: a randomized phase III EORTC 30853 Study. Cancer 1990; 66 (Suppl. 5): 104557
  • 27
    Denis L, Robinson M, Mahler C et al. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853). J Steroid Biochem Mol Biol 1990; 37: 9519
  • 28
    Navratil H. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results of 49 cases from a multicentre study. Progress in Clinical and Biological Research, Prostate Cancer Part A. Research, Endocrine Treatment, and Histopathology. Proceedings of the 2nd International Symposium on Prostate Cancer, France 1986. New York: Alan R. Liss, Inc., 1987: 40110
  • 29
    Brisset J-M, Boccon-Gibod L, Botto H et al. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: A multicentre comparative study of two doses of the drug and of a placebo. Progress in Clinical and Biological Research, Prostate cancer Part A. Research, Endocrine Treatment, and Histopathology. Proceedings of the 2nd International Symposium on Prostate Cancer, France 1986. New York: Alan R. Liss, Inc., 1987: 41122
  • 30
    Namer M, Toubol J, Caty A et al. A randomized double-blind study evaluating Anandron associated with orchidectomy in stage D prostate cancer. J Steroid Biochem Mol Biol 1990; 37: 90915
  • 31
    Schulze H, Kaldenhoff H, Senge T. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer. Urol Int 1988; 43: 1937
  • 32
    Robinson MRG. EORTC protocol 30805: A phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Progress in Clinical and Biological Research, Management of Advanced Cancer of Prostate and Bladder. New York: Alan R Liss Inc, 1988: 10110
  • 33
    Robinson MRG. Complete androgen blockade: The EORTC experience comparing orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate. Progress in Clinical and Biological Research, Prostate cancer Part A. Research, Endocrine Treatment and Histopathology. Proceedings of the 2nd International Symposium on Prostate Cancer, France 1986. New York: Alan R Liss, Inc., 1987: 38390
  • 34
    Boccardo F, Pace M, Rubagotti A et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29A: 108893
  • 35
    Fourcade RO, Colombel P, Mangin M et al. ‘Zoladex’ plus flutamide versus ‘Zoladex’ plus placebo in advanced prostatic carcinoma: extended follow up of the French multicentre study. In MurphyD, KhouryS, ChatelainC, DenisL eds, Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer: Diagnosis and Treatment. June 1992, Paris, France 1993: 1026
  • 36
    Fourcade RO, Cariou G, Coloby P et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostate carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol 1990; 18 (Suppl. 3): 457
  • 37
    Crawford ED, Smith JA, Soloway MS et al. A randomised controlled clinical trial of leuprolide and Anandron versus leuprolide and placebo for advanced prostate cancer. J Urol 1990; 143: 221A
  • 38
    Peto R. Immediate hormonal treatment ‘does not improve survival’. Eur J Cancer 1998; 34: 67
  • 39
    Denis LJ, Keuppens F, Smith PH et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 1998; 33: 14451
  • 40
    Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158: 1603
  • 41
    Eisenberger MA, Blumenstein BA, Crawford D et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 1998; 339: 103642
  • 42
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 2659
  • 43
    Klotz LH & Newman T and the Ontario Practice Guidelines Initiative (OCTRF). Total androgen blockade for metastatic prostate cancer: history and analysis of the PCTCG overview. Can J Urol 1996; 3 (Suppl. 1): 1025
  • 44
    Caubet JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 718DOI: 10.1016/s0090-4295(96)00325-1
  • 45
    Debruyne FM, De Gery A, Hucher M et al. Maximum androgen blockade nilutamide combined with orchidectomy in advanced prostate cancer: an updated meta-analysis of 7 randomised placebo-controlled trials (1191 patients). Eur Urol 1996; 30 (Suppl. 2): 264(A990)
  • 46
    Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximal androgen blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomised controlled trials and 4128 patients using flutamide. Prost Canc Prost Dis 1999; 2: 48
  • 47
    AHCPR. Evidence-based Practice Center of the Blue Cross and Blue Shield Association. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment for advanced prostatic cancer. 2000. http://www.ahcpr.gov
  • 48
    Oxman AD, Guyatt GH, Singer J et al. Agreement among reviewers of review articles. J Clin Epidemiol 1991; 44: 918
  • 49
    Oxman AD, Cook DJ, Guyatt GH. Users' guides to medical literature. VI. How to use an overview. Evidence-based Medicine Working Group. JAMA 1994; 272: 136771
  • 50
    Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. New Engl J Med 1987; 316: 4505
  • 51
    Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomised controlled trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995; 48: 16771DOI: 10.1016/0895-4356(94)00172-m
  • 52
    Oxman AD, Clarke MJ, Stewart LA. From science to practice. Meta-analyses using individual patient data are needed. JAMA 1995; 274: 8456
  • 53
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 40812
  • 54
    Cook DJ, Guyatt GH, Ryan G et al. Should unpublished data be included in meta-analyses? JAMA 1993; 269: 274953
  • 55
    Klotz LH & Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Can J Urol 1996; 3: 24650
  • 56
    Kelly WK & Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 6079
  • 57
    Nieh PT. Withdrawal phenomenon with the antiandrogen Casodex. J Urol 1995; 153: 10703
  • 58
    Small EJ, Schellhammer P, Venner G et al. A double-blind assessment of antiandrogen withdrawal from Casodex (C) or Eulexin (E) therapy while continuing luteinizing hormone-releasing hormone analogue (LHRH-a) therapy for patients with stage D2 prostate cancer. J Urol 1995; 157: 17315
  • 59
    Huan SD, Gerridzen RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 6324
  • 60
    Akakura K, Akimoto S, Furuya Y, Ito H. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur Urol 1998; 33: 56771
  • 61
    Janknegt RA, Abbou CC, Bartoletti R et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 7783
  • 62
    Moinpour CM, Savage MJ, Troxel A et al. Quality of life in advanced prostate cancer: results of a randomised therapeutic trial. J Natl Cancer Inst 1998; 90: 153743DOI: 10.1093/jnci/90.20.1537
  • 63
    Oefelein MG & Cornum R. Failure to achieve castrate levels of T with LHRH agonists. J Urol 2000; 164: 7269
  • 64
    Kolvenbag GJCM, Furr BJA, Blackledge GRP. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prost Canc Prost Dis 1998; 1: 30714
  • 65
    Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 10314
  • 66
    Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 54748
  • 67
    Sadar M. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999; 274: 777783
  • 68
    Klocker H, Culig Z, Eder IE et al. Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Eur Urol 1999; 35: 41320
  • 69
    Joyce R, Fenton MA, Rode P et al. High-dose bicalutamide for androgen-independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 14953
  • 70
    Palmberg C, Koivisto P, Hyytinen E et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997; 31: 2169
  • 71
    Small EJ & Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15: 3828
  • 72
    Sarosdy MF, Schellhammer PF, Sharifi R et al. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology 1998; 52: 828DOI: 10.1016/s0090-4295(98)00145-9
  • 73
    Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 19925
  • 74
    Labrie F & Candas B. Androgen blockade in prostate cancer. Lancet 2000; 356: 33644
  • 75
    McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 1827